NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Nov 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
19
Mechanism of Action
DNA Terminase Complex Inhibitors
Pharmacologic Class:
Cytomegalovirus DNA Terminase Complex Inhibitor
Clinical Trials (5)
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Started Feb 2026
40 enrolled
Cytomegalovirus Prophylaxis
Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysis
Started Sep 2025
20 enrolled
End-Stage Kidney Disease (ESKD)
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
Started Aug 2024
90 enrolled
Cytomegalovirus InfectionsKidney Transplant InfectionPancreas Transplant
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
Started Apr 2024
80 enrolled
Cytomegalovirus InfectionsTransplant-Related Disorder
Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.
Started Oct 2023
90 enrolled
Infections, Cytomegalovirus
Loss of Exclusivity
LOE Date
Feb 28, 2033
85 months away
Patent Expiry
Feb 28, 2033
Exclusivity Expiry
Aug 30, 2031